Related Experiment Video

Updated: Nov 19, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.6K

Canakinumab for secondary prevention of coronary artery disease

Luis Ortega-Paz1, Davide Capodanno2, Dominick J Angiolillo3

  • 1Cardiovascular Institute, Hospital Clinic, IDIBAPS, Barcelona, 08036, Spain.

Future Cardiology
|February 3, 2021
PubMed

Insights

Inflammation drives cardiovascular disease (CVD). The drug canakinumab targets IL-1β, showing promise for preventing recurrent events and offering new therapeutic avenues for CVD secondary prevention.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Cardiovascular diseases (CVD) are a leading global cause of mortality.
  • Inflammation is a recognized contributor to atherosclerosis and its complications.
  • Targeting inflammation for CVD secondary prevention requires further investigation.

Purpose of the Study:

  • To review the pharmacology of canakinumab.
  • To discuss the clinical development status of canakinumab.
  • To outline regulatory perspectives for canakinumab in CVD.

Main Methods:

  • Review of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial.
  • Analysis of canakinumab's mechanism of action as an IL-1β inhibitor.
  • Synthesis of current clinical data and regulatory information.

Main Results:

  • The CANTOS trial validated the role of inflammation in atherosclerotic disease.
  • Canakinumab, a monoclonal antibody, targets the IL-1β inflammatory pathway.
  • Canakinumab demonstrated efficacy in reducing recurrent cardiovascular events.

Conclusions:

  • Canakinumab represents a novel therapeutic strategy for secondary CVD prevention.
  • Targeting IL-1β inflammation opens a new era for CVD treatment.
  • Further research and regulatory evaluation are ongoing for canakinumab.

Keywords:
IL-1βcanakinumabinflammation

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
475
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
113
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
219
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
123
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
124
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
146